Upcoming meetings

The fall conference season provides abundant opportunities to attend conferences that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions, and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

Upcoming meetings

The winter conference season provides ample opportunities to attend conferences that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions, and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

2010 upcoming meetings

The spring/summer 2010 conference season provides ample opportunities to attend conferences that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions, and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

2012 Upcoming Meetings

The Summer/Fall 2012 conference season provides ample opportunities to attend meetings that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

Upcoming meetings

The winter/spring 2010 conference season provides ample opportunities to attend conferences that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions, and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

2012 Upcoming Meetings

The Fall/Winter 2012 conference season provides ample opportunities to attend meetings that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

2010 upcoming meetings

The summer and fall 2010 conference seasons provide ample opportunities to attend conferences that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions, and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

Upcoming meetings

The spring meeting season is gearing up, and numerous conferences that feature topics relevant to antibody research and development (R&D) will be held during March, April and May 2009. Meetings such as these serve critical informational and educational functions, and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

2012–13 Upcoming meetings

The Winter 2012–13 conference season provides ample opportunities to attend meetings that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.

Please note that Upcoming meetings lists will no longer be included in the print version of mAbs starting with the January/February 2013 issue. Please visit the mAbs home page to find an online meeting list: www.landesbioscience.com/journals/mabs/     

2012 upcoming meetings

The Summer 2012 conference season provides ample opportunities to attend meetings that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

2012 Upcoming Meetings

The Fall/Winter 2012 conference season provides ample opportunities to attend meetings that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

2012 Upcoming Meetings

The Summer/Fall 2012 conference season provides ample opportunities to attend meetings that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D.     

mAbs’s communication networks

Since its start in 2009, mAbs has actively contributed to the communication networks among our readers. One way we achieve this is by publishing highly detailed reports of numerous meetings, conferences, summits, forums and congresses focused on antibody research and development (R&D) that are held in the US and Europe. The meetings serve critical informational and educational functions and are valuable networking opportunities, and mAbs is pleased to serve the antibody community by providing published records of the proceedings. PDFs of the meeting reports are generously made open access by the publisher of mAbs.     

2012–13 Upcoming meetings

The Winter 2012–13 conference season provides ample opportunities to attend meetings that feature topics relevant to antibody research and development (R&D). Meetings such as these serve critical informational and educational functions and are key networking opportunities. Locations are spread throughout the world, reflecting the global nature of antibody R&D. Please note that Upcoming meetings lists will no longer be included in the print version of mAbs starting with the January/February 2013 issue. Please visit the mAbs home page to find an online meeting list: www.landesbioscience.com/journals/mabs/     

De novo discovery of antibody drugs – great promise demands scrutiny

ABSTRACT

We live in an era of rapidly advancing computing capacity and algorithmic sophistication. “Big data” and “artificial intelligence”find progressively wider use in all spheres of human activity, including healthcare. A diverse array of computational technologies is being applied with increasing frequency to antibody drug research and development (R&D). Their successful applications are met with great interest due to the potential for accelerating and streamlining the antibody R&D process. While this excitement is very likely justified in the long term, it is less likely that the transition from the first use to routine practice will escape challenges that other new technologies had experienced before they began to blossom. This transition typically requires many cycles of iterative learning that rely on the deconstruction of the technology to understand its pitfalls and define vectors for optimization. The study by Vasquez et al. identifies a key obstacle to such learning: the lack of transparency regarding methodology in computational antibody design reports, which has the potential to mislead the community efforts     

4th European Antibody Congress 2008: December 1-3, 2008, Geneva,Switzerland

The Fourth European Antibody meeting, organized by Terrapin Ltd, was held in Geneva, a center of the European biopharmaceutical industry. Merck-Serono, NovImmune, Pierre Fabre, and Therapeomic are located nearby, as are R&D centers of Boehringer-Ingelheim, Novartis, Roche and Sanofi-Aventis. Over 40 speakers and more than 200 delegates attended the event. Companies represented included Abbott, Ablynx, Adnexus/ BMS, Astra-Zeneca/ CAT/ Medimmune, BiogenIdec, BioRad, Centocor (Johnson & Johnson), Crucell/ DSM, Domantis, Dyax, Genmab, Genzyme, Glycart/ Roche, Haptogen, Immunogen, Kyowa-Kirin, LFB, Medarex, Merck-Serono, Micromet, Novartis, Pierre Fabre Laboratories, Roche, Sanofi-Aventis, Seattle-Genetics, Transgene, UCB Celltech, and Wyeth. Other attendees included those based in academe or government (University of Amsterdam, University of Zurich, Univeristy Hospital-Lyon, Ecole Polytechnique Federale de Lausanne, INSERM, Tufts University, US National Institutes of Health), consultants, and patent attorneys (Edwards, Angell, Palmer & Dodge). The meeting was very interactive, and included exchanges during the many scheduled networking times (exhibitions, speed-networking, lunches, and evening receptions). The first day of the 3-day conference was dedicated to advances in understanding antibody structure-function relationships. Challenges and opportunities in antibody development were the focus of the second day, and the third day featured discussion of innovative antibodies and antibody alternatives.     

Evolving patterns in a collaboration network of global R&D on monoclonal antibodies

We investigated the evolution process of collaborative inter-organizational network of the research and development (R&D) on monoclonal antibody (mAb) over the past 30 y. The annual detection of the collaboration network provides dynamics on network structures and relationship changes among different organizations. Our research showed continuous growth of the network's scale and complexity due to the constant entry of new organizations and the forging of new partnering relationships. The evolving topological features reveal a core-periphery structure that became clearer over time and an increasing heterogeneity within the collaborative mAb R&D network. As measured by the number of network participants, dedicated biotechnology firms (DBFs) were the dominant organization form in the field of mAb development, but their average centrality was reduced during the period of 2004–2009, when pharmaceutical companies took over the positions of DBFs. Along with the network evolution, 2 waves of substitution on the leading positions were driven by technological innovations and mergers and acquisitions (M&A). In addition, this study analyzed organizational-level behaviors to help understand the evolution of network structures over the field of mAb development across the different technologically innovative or economic contexts.     

Integrating process engineering and microbiology tools to advance activated sludge wastewater treatment research and development

Wastewater treatment is a huge industryworldwide. Despite the massive capital andoperating costs, only a relatively small amountof R&D investment is made. This might havebeen related to the limited demands in terms ofeffluent quality in the past, but today'senvironmental awareness requires much strictereffluent standards to be achieved. This inturn should give sufficient incentives,together with the possible large cost savings,to increase the R&D activities in this field. There are certainly significant knowledge gapsto be filled and substantial benefits could begained from this.A range of knowledge gaps are identified inthis paper, extending from the role ofintermediates in nutrient removal overparameter estimation in modelling andsimulation to understanding the microbialmetabolic pathways at a genetic and enzymaticlevel. These gaps are opportunities andchallenges for all researchers andprofessionals in this field. Addressing themwill help substantially in the continuingdevelopment of wastewater treatmenttechnologies.The complexity of biological wastewatertreatment processes requires a broad range oftools and expertise to address the knowledgegaps. Novel process analysis tools arecritically important to investigate biologicaltreatment processes in future. They will comefrom different expertise areas and will need tobe used in close integration to gain maximalbenefits from the efforts. These tools willlikely include respirometry, novel chemicalanalyses, microsensors, gene-basedidentification, microbial physiology techniquesand integrated modelling and simulation. Examples of the application of such techniquesare provided to demonstrate the way thesetechniques may be used in future. In the nextfew years, there is likely an exciting andhighly interactive period of research anddevelopment for the wastewater industry.     

III–V dry processing from R&D to production

Issues relating to the use of III–V dry processing for device fabrication in R&D and production are critically important. Of particular concern are current process and equipment limits which can prevent scaling to full device production.